Laurence Albigès's profile photo

Laurence Albigès

Featured in: Favicon nature.com Favicon oup.com Favicon sagepub.com (+1) Favicon jamanetwork.com Favicon nejm.org Favicon thelancet.com Favicon newsbreak.com Favicon aacrjournals.org Favicon ascopubs.org Favicon cancernetwork.com

Articles

  • CheckMate 67T: Subcutaneous Nivolumab Non-Inferior to Intravenous in Advanced RCC - Laurence Albiges

    Nov 1, 2024 | urotoday.com | Laurence Albigès

    Read the Full Video TranscriptZachary Klaassen: Hi, my name is Zach Klaassen. I'm a urological oncologist at the Georgia Cancer Center in Augusta, Georgia. I'm delighted to be joined today by Professor Laurence Albiges from Gustave Roussy in Paris, France, medical oncologist. Laurence, thanks very much for joining us today. Laurence Albiges: Thank you very much for having me. Zachary Klaassen: So we're going to talk about some exciting ESMO data you presented, specifically CheckMate 67T.

  • Summary and Forward Looking for RCC

    Sep 9, 2024 | onclive.com | Laurence Albigès

    Summary and Forward Looking for RCCIn her concluding remarks, Laurence Albiges, MD, PhD, shares her final thoughts and expresses optimism for the future landscape of renal cell carcinoma treatments.

  • Biomarker-driven combination treatment approach in non-clear cell RCC (Met-driven)

    Sep 3, 2024 | onclive.com | Laurence Albigès

    OpinionVideoSeptember 3, 2024Author(s):Dr. Laurence Albiges, MD, PhD, reviews the recent findings presented at the American Society of Clinical Oncology (ASCO) 2024 meeting, specifically focusing on the results of the phase 3 STELLAR trial.

  • Emerging Therapies in the Front-line Setting of Advanced non-clear cell RCC

    Aug 26, 2024 | onclive.com | Laurence Albigès

    OpinionVideoAugust 26, 2024Author(s):A key opinion leader discusses alternative therapies for the first-line treatment of advanced non-clear cell renal cell carcinoma (RCC), focusing on the PAPMET regimen and the results of a relevant Phase 2 clinical study. Video content above is prompted by the following:Please review some of the other therapies for the treatment of advanced non-clear cell RCC in the front-line setting:PAPMET (Tripathi A et al.

  • Dr Albiges Reviews Long term follow up data from KEYNOTE-B61

    Aug 19, 2024 | onclive.com | Laurence Albigès

    OpinionVideoAugust 19, 2024Author(s):Laurence Albiges, MD, PhD, analyzes the long-term follow-up data from the phase 2 KEYNOTE-B61 study, highlighting the observed overall survival (OS) rate associated with adjuvant pembrolizumab. Please discuss long term follow up data from the phase 2 KEYNOTE-B61 study investigatingpembrolizumab + lenvatinib in the first-line treatment of advanced non-clear cell RCC.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →